Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2002

View Archived Issues

Orally active acetylcholinesterase and 5-HT uptake inhibitor proposed for Alzheimer's disease

Protopic cleared for launch in Europe

GK-04489, a new compound with efficacy in arterial thrombosis and cerebral ischemia

Findings presented at AAAAI meeting further support development of Genaera's mucoregulator

BIA-2-024, a new antiepileptic drug, evaluated for metabolism in animals and in vitro

NeoTherapeutics develops promising new family of antipsychotic drugs

Potent and selective integrin inhibitors synthesized at Celltech

First phase I trial of anti-HIV-1 human MAbs assessing safety and pharmacokinetics

ICAgen research leads to two new series of antiarrhythmic agents

GSK describes novel fatty acid synthase FabH inhibitors for bacterial infections

Signal discloses a novel group of JNK inhibitors for a wide range of conditions

More thrombin inhibitors in development at Merck

Antitumor activity of AN-238 against human colorectal cancers independent of p53 status

ISIS-104838 enters second phase II trial in RA

Collateral Therapeutics gains rights to EPAS1 gene

Phase I results show Product R to be safe and well tolerated

Cambrex to manufacture Bioheart's MyoCell therapy

IL-9 blockade continues to show promise for the treatment of asthma

Extended-release Zerit has similar virological activity to immediate-release drug

Risperdal approved for delaying schizophrenia relapse in U.S.

Trisenox approved in Europe for acute promyelocytic leukemia

Keryx initiates phase II dosing of KRX-101 in HIV-associated nephropathy

Third of three phase III trials under way for AC-2993 in treatment of type 2 diabetes

Bavarian Nordic reviews 2001 progress, 2002 outlook

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...